Multiple Myeloma Hub
What are the pros and cons of bispecific antibodies for multiple myeloma?
Jul 25, 2022
Experts Roberto Mina and Andrzej J. Jakubowiak discuss the pros and cons of bispecific antibodies for multiple myeloma, highlighting MajesTEC-1 and MagnetisMM-1 trials, efficacy, response rates, challenges like infection risks, comparison to CAR T-cell therapies, and sequencing of therapies in myeloma treatment.
27:57
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Bi-specific antibodies show promising efficacy comparable to CAR-T therapy in multiple myeloma treatment.
- Careful monitoring is needed to manage infection risks and CRS challenges associated with bi-specific antibodies for multiple myeloma.
Deep dives
Efficacy and Response Rates of Bi-Specific Antibodies
Bi-specific antibodies show high efficacy with around two-thirds of patients responding and one-third achieving complete remission, even in heavily pre-treated populations. Results indicate promising efficacy comparable to CAR-T therapy, especially after previous BCMA targeting therapies. Alternative targeting strategies like GPRC5D also show promising activity, suggesting the potential for sequence or combination treatments.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
